Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate
References (22)
- et al.
In vivo conversion of norethisterone to ethynyloestradiol in perimenopausal women
J Steroid Biochem Mol Biol
(1990) - et al.
Metabolic clearance rate of oestrone sulphate in post-menopausal women
Maturitas
(1984) - et al.
Comparative metabolism of oestrone sulphate after oral and intravenous administration in post-menopausal women
Maturitas
(1987) - et al.
Effect of orally administered oestrogens on circulating oestrogen profiles in post-menopausal women
Maturitas
(1989) - et al.
Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in postmenopausal women
Maturitas
(1990) - et al.
Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone
Maturitas
(1993) - et al.
Serum levels and pharmacokinetics of norethisterone after ingestion of lynestrenol: its relation to dose and stage of the menstrual cycle
Contraception
(1982) - et al.
Steroid dynamics under steady-state conditions
Rec Prog Horm Res
(1969) Inhibition of oral contraceptive steroidmetabolizing enzymes by steroids and drugs
Am J Obstet Gynecol
(1990)- et al.
Conversion of androstenedione to estrone by human fat tissue
J Clin Endocrinol Metab
(1972)
Aromatization by skeletal muscle
J Clin Endocrinol Metab
(1986)
Cited by (38)
A comparative characterization of estrogens used in hormone therapy via estrogen receptor (ER)-α and -β
2017, Journal of Steroid Biochemistry and Molecular BiologyCitation Excerpt :Whether our findings are physiologically relevant, would depend on serum concentrations in women using these estrogens in HT. These serum levels range between 0.1 nM and 8.6 nM for E2 [122–125], 0.5 nM and 0.6 nM for E3 [126], 0.1 nM and 10 nM for E1 [124,125,127], and 0.06 nM and 0.13 nM for EE [122,128]. The fact that we show maximal responses between 0.1 pM and 1 nM for regulation of gene expression and breast cancer cell proliferation highlights the potential of the estrogens evaluated in this study to display similar effects in vivo.
Progestogen therapies: Differences in clinical effects?
2004, Trends in Endocrinology and MetabolismOverview on the effects of progestins on bone
2003, Maturitas
Copyright © 1995 Published by Elsevier Ireland Ltd.